Cancer 'smart bomb' created from a crocus
September 13, 2011 by Deborah Braconnier in Cancer
Colchicum autumnale autumn crocus. Image: Luc Viatour/ Wikipedia.
(PhysOrg.com) -- Scientists from the UK have figured out a way to turn chemicals found in the crocus flower which blooms throughout the UK into a smart bomb of sorts when it comes to a new cancer medication. This new treatment may potentially create a drug that is capable of targeting cancerous tumors, such as associated with breast, colon, lung and prostate, without causing any side effects.
The researchers, from the Institute for Cancer Therapeutics at the University of Bradford, have published their work in Cancer Research and had it showcased at the recent British Science Festival.
While the native British Autumn crocus has been known for a long time for its anti-inflammatory and anti-cancer properties, its chemical colchicine is unfortunately also toxic to other cells within the human body. For this reason, the use of the crocus and the chemical colchicine has not been used for medical treatments.
The researchers, led by Professor Laurence Patterson, have found a way around the toxic nature of the chemical when it comes to healthy tissue in the body and determined a way to focus the toxicity towards the cancerous tumor. By attaching a chemical 'tail' to the colchicine molecule, the researchers have been able to deactivate the toxic properties until it reaches the targeted cancer. Cancer tumors contain an enzyme called MMP and this enzyme effectively removes the tail and activates the colchicine. Once activated, the colchicine goes into action breaking up the blood vessels that feed the tumor and essential starve it. Because the drug is activated in the tumor, it does not affect outside tissue and no side effects have been noted.
At this time, tests have only been conducted on mice but the results have been remarkable. In mice testing, all mice have responded to the treatment and in as many as half of the studies, the mice appeared cured of the cancer. The drug is effective toward cancers that produce tumors and the researchers have tested breast, colon, lung, prostate and sarcoma tumors at this point.
Clinical trials on human patients are expected to being in as soon as 18 months and will be conducted at St. Jamess University Hospital. The researchers hope that if the clinical trials prove successful, a new drug could be available within the next six to seven years.
© 2011 PhysOrg.com
-
New cancer treatment targets both tumor cells and blood vessels
Jun 18, 2008 |
not rated yet |
0
-
Using nanotechnology to improve cancer treatment
Dec 03, 2010 |
not rated yet |
0
-
FDA acts against unapproved colchicine
Feb 06, 2008 |
not rated yet |
0
-
Drug kills prostate tumor cells
Aug 11, 2006 |
not rated yet |
0
-
A longer lasting tumor blocker
Apr 28, 2009 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
18 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
-
portable metabolism meter?
May 21, 2012
-
Rare medical conditions on 20/20 tonight
May 18, 2012
-
"Good" Cholesterol in Doubt
May 17, 2012
- More from Physics Forums - Medical Sciences
More news stories
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Cancer
12 hours ago |
not rated yet |
0
|
Pancreatectomy OK without downstaging from therapy
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...
Cancer
13 hours ago |
not rated yet |
0
Common therapies for basal cell carcinoma offer similar survival
(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...
Cancer
14 hours ago |
not rated yet |
0
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Cancer
16 hours ago |
not rated yet |
0
|
New prostate cancer screening guidelines face a tough sell, study suggests
(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...
Cancer
19 hours ago |
not rated yet |
1
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Tongue analysis software uses ancient Chinese medicine to warn of disease
For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare
A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...
New device allows pacemaker patients to safely undergo MRIs
For many, it's a medical conundrum: The very pacemaker keeping their heart in rhythm prevents them from undergoing an MRI to diagnose other ailments, because interaction between the two devices could prove deadly.
First study to suggest that the immune system may protect against Alzheimer's changes in humans
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.
Sep 13, 2011
Rank: 4.5 / 5 (2)
Woha...usually stuff like this sounds too good to be true. But in this case the simplicity and elegance of the method makes me hope that something will come of it.
Sep 13, 2011
Rank: 5 / 5 (1)
I'm well familiar with Colchicine, have worked with it to induce polyploids in plants ( old school GMO's baby :).
Methinks the author of this here article needs to go crack some books.
http://en.wikiped...lchicine
Sep 13, 2011
Rank: not rated yet
why so long ? ill people doesn't have a time,better is to die from the cancer or take little risk and use this new treatment now ?
Sep 13, 2011
Rank: 5 / 5 (2)
There's several phases which a drug will have to go through before being approved.
http://en.wikiped...al_trial
This takes considerable time.
Sep 14, 2011
Rank: not rated yet
See Gout, treatment.
Sep 19, 2011
Rank: not rated yet